A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

por Warso, M A, Richards, J M, Mehta, D, Christov, K, Schaeffer, C, Rae Bressler, L, Yamada, T, Majumdar, D, Kennedy, S A, Beattie, C W, Das Gupta, T K
Publicado 2013